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Abstract
 
The T cell antigen receptor complexes expressed on 
 
  
 
 and 
 
  
 
 T cells differ not only in their
respective clonotypic heterodimers but also in the subunit composition of their CD3 com-
plexes. The 
 
   
 
T cell receptors (TCRs) expressed on ex vivo 
 
  
 
 T cells lack CD3
 
 
 
, whereas
 
   
 
TCRs contain CD3
 
 
 
. While this result correlates with the phenotype of CD3
 
 
 
 
 
/
 
 
 
 mice, in
which 
 
  
 
 T cell development is unaffected, it is inconsistent with the results of previous studies
reporting that CD3
 
 
 
 is a component of the 
 
   
 
TCR. Since earlier studies examined the sub-
unit composition of 
 
   
 
TCRs expressed on activated and expanded peripheral 
 
  
 
 T cells or 
 
  
 
TCR
 
 
 
 intestinal intraepithelial lymphocytes, we hypothesized that activation and expansion
may lead to changes in the CD3 subunit composition of the 
 
   
 
TCR. Here, we report that ac-
tivation and expansion do in fact result in the inclusion of a protein, comparable in mass and
mobility to CD3
 
 
 
, in the 
 
   
 
TCR. Further analyses revealed that this protein is not CD3
 
 
 
, but
instead is a differentially glycosylated form of CD3
 
 
 
. These results provide further evidence for
a major difference in the subunit composition of 
 
  
 
- and 
 
   
 
TCR complexes and raise the
possibility that modification of CD3
 
 
 
 may have important functional consequences in activated
 
  
 
 T cells.
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Introduction
 
The antigen receptor on T cells is a multisubunit complex
composed of a clonotypic heterodimer and four invariant
signaling subunits, CD3
 
 
 
, CD3
 
 
 
, CD3
 
 
 
, and TCR-
 
 
 
. The
generally accepted stoichiometry of the 
 
   
 
TCR is non-
 
  
 
TCR-
 
  
 
, CD3
 
  
 
, CD3
 
  
 
, and TCR-
 
   
 
(1). Previous
data obtained from expanded populations of peripheral 
 
  
 
T cells suggested a similar structure for the 
 
   
 
TCR, except
that the 
 
   
 
TCR could contain the TCR-
 
 
 
 family mem-
ber, Fc
 
 
 
R1 
 
 
 
 (FcR
 
 
 
), as a homodimer or as a heterodimer
with TCR-
 
 
 
 in lieu of the TCR-
 
 
 
 homodimer (2). How-
ever, recent data have called for a revision in this model of
 
   
 
TCR structure. For example, the observation that
FcR
 
 
 
 is a component of the 
 
   
 
TCR conflicts with the
findings that FcR
 
 
 
 transcripts are not detected in purified
thymic and peripheral 
 
  
 
 T cells (3) and that 
 
  
 
 T cell de-
velopment is unaffected in FcR
 
 
 
 
 
/
 
 
 
 mice (4, 5). We ex-
tended these studies by analyzing the subunit composition
of 
 
   
 
TCR complexes on ex vivo 
 
  
 
 T cells from 
 
   
 
TCR
Tg and non
 
  
 
-TCR Tg mice (6). Biochemical analyses
showed that TCR-
 
 
 
 is a component of the 
 
   
 
TCR on ex
vivo 
 
  
 
 T cells, while FcR
 
 
 
 is not. However, after in vitro
activation and expansion, FcR
 
 
 
 is expressed and incorpo-
rated into the 
 
   
 
TCR complex (6). These data show that
activation and expansion induce changes in the 
 
   
 
TCR
complex and demonstrate that the subunit composition of
 
   
 
TCRs expressed by activated and expanded populations
of 
 
  
 
 T cells does not accurately represent the subunit
composition of TCR complexes expressed by primary 
 
  
 
T cells.
A more striking inconsistency with the previous model
of 
 
   
 
TCR structure was the finding that the 
 
   
 
TCRs ex-
pressed on ex vivo thymic and lymph node 
 
  
 
 T cells do
not contain CD3
 
 
 
 (6). This result appears to contradict
previous studies, in which the CD3 subunit composition of
the 
 
   
 
TCR and 
 
   
 
TCR was found to be identical (2, 7,
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8). As these previous studies used expanded populations of
peripheral 
 
  
 
 T cells, 
 
   
 
TCR
 
 
 
 intestinal intraepithelial
lymphocytes (iIELs)
 
*
 
 and 
 
  
 
 T cell hybridomas as sources
of 
 
  
 
 T cells, it is possible that activation and expansion in-
duced a change in the subunit composition of the CD3
complex. To test this, we compared the subunit composi-
tion of TCR complexes expressed by 
 
  
 
 T cells before and
after in vitro activation and expansion. Here, we report the
detection of a protein, equivalent in mass to CD3
 
 
 
, in the
 
   
 
TCR after activation and expansion. Biochemical anal-
yses revealed that this protein was not CD3
 
 
 
 but a differen-
tially glycosylated form of CD3
 
 
 
. In addition, modification
of the CD3
 
 
 
 subunit was observed in in vitro–activated 
 
  
 
T cells and in iIELs.
Together, these results demonstrate that the protein ini-
tially thought to be CD3
 
 
 
 in the 
 
   
 
TCR complex is, in-
stead, a differentially glycosylated form of CD3
 
 
 
 and provide
further substantiation for the conclusion that the 
 
   
 
TCR
and 
 
   
 
TCR complexes differ in their subunit composition.
 
Materials and Methods
 
Mice.
 
B6.129-TCR-
 
 
 
 
 
/
 
 
 
 (TCR-
 
 
 
 
 
/
 
 
 
) mice (9) were pur-
chased from The Jackson Laboratory. C57BL/6 (B6), C57BL/6-
V
 
 
 
6-J
 
 
 
1-C
 
 
 
1/V
 
 
 
1-D 2-J 2-C     TCR Tg (   TCR Tg, line
134) (10), and C57BL/6-CD3  /  (CD3  / ) (11) mice were
maintained in our animal facility. All experimental mice were
killed at 5–8 wk of age.
Antibodies. Antibodies used for cell separation were FITC-
labeled anti-CD19 (1D3), FITC-labeled anti–I-Ab (AF6–120.1),
FITC-labeled anti-CD4 (RM4–5), FITC-labeled anti-CD8 
(53–6.7), and FITC-labeled anti–TCR-  (H57–597), all of
which were purchased from BD PharMingen. Antibodies used
for stimulation and biochemical analysis were anti-  TCR
(UC7–13D5 and GL4), anti–TCR-  (H57–597), and CD3 
(145–2C11) (BD PharMingen), hamster anti–TCR-  (H146) and
hamster anti-CD3  (H25) (provided by D. Wiest, Fox Chase
Cancer Center, Philadelphia, PA), rabbit anti-CD3  (R9) (pro-
vided by L. Samelson, National Institutes of Health, Bethesda,
MD), goat anti-CD3  and goat anti-CD3  (Santa Cruz Biotech-
nology, Inc.), HRP-conjugated Protein A (Transduction Labora-
tories), and donkey anti–goat IgG (H   L)-HRP (Jackson Im-
munoResearch Laboratories).
Isolation of iIELs. iIELs were isolated as described previously
(12).
Cell Separation. Peripheral    and    T cells were purified
from lymph node cells from B6 and    TCR Tg mice, respec-
tively, using the MACS® magnetic bead separation system
(Miltenyi Biotec) as described previously (6). The purity of the
resulting cell populations was typically 98% for    T cells and
99% for    T cells.
Stimulation and Expansion of T Cells In Vitro. 3   106 unfrac-
tionated lymph node cells were stimulated on 6-well plates
coated with anti-  TCR mAb (10  g/ml GL4), anti–TCR- 
mAb (10  g/ml H57–597), or anti-V 1 mAb (10  g/ml 2.11;
reference 13) for 2 d and then expanded in the presence of 40
U/ml of murine rIL-2 (Peprotech, Inc.) for 2–12 more days to
replicate conditions used in previous studies (2, 6). Unless other-
wise noted, stimulated    and    T cells were harvested and an-
alyzed 6 d after activation. Phenotypic analysis on day 6 revealed
that cultures stimulated with anti-  TCR mAb or with anti-V 1
mAb were 100%    TCR  or V 1 , respectively. Similarly, cul-
tures of B6 and CD3  /  lymph node cells stimulated with anti-
  TCR mAb were 100%    TCR  and were predominantly
CD4  CD8 . The only major difference detected between the
B6 and CD3  / –stimulated    T cells was in the level of
   TCR expression, with the level of surface TCR on CD3  / 
   T cells being seven to eightfold less than that observed on
B6    T cells.
Surface Biotinylation. Biotinylation of surface proteins on puri-
fied    and    T cells was performed as described previously (6).
Deglycosylation of TCR Subunits. Removal of N-linked gly-
cans from glycoproteins in the TCR complex has been described
previously (14). In brief, immunoprecipitated TCR proteins
were denatured by boiling in 1% SDS/1% 2-mercaptoethanol for
5 min. The eluted proteins were neutralized by the addition of
10% NP-40 and then resuspended in the reaction buffer provided
by the manufacturer (New England Biolabs). Each sample was
treated with 2,500 U peptide-N-glycosidase F (PNGase F; New
England Biolabs) and then allowed to incubate overnight at room
temperature. The digestion reaction was quenched with 2  SDS
sample buffer containing 2-mercaptoethanol.
Protein Analysis. Immunoprecipitations and immunoblotting
were performed as described previously (15), except that cells
were lysed in a buffer containing 20 mM Tris, pH 7.5, 150 mM
NaCl, 1 mM EDTA, 1 mM Na3VO4, protease inhibitors (Roche
Laboratories), and 1% Triton X-100 (Calbiochem). Two-dimen-
sional (2-D) SDS-PAGE analysis of TCR subunits has been de-
scribed previously (6). Biotinylated surface proteins were de-
tected using ABC-HRP (Vector Laboratories) and the ECL
Western blot detection system (Amersham Pharmacia Biotech).
Results and Discussion
Alteration in the CD3 Subunit Composition of the    TCR
After TCR Stimulation. To determine whether in vitro
activation and expansion lead to changes in the CD3 sub-
unit composition of the    TCR, we compared the sub-
unit composition of surface CD3 complexes expressed by
primary and in vitro activated and expanded    T cells
from V 6-J 1-C 1/V 1-D 2-J 2-C     TCR Tg (   TCR
Tg) mice (10). As shown in Fig. 1, 2-D SDS-PAGE analy-
sis of anti-  TCR immunoprecipitates revealed the pres-
ence of a 26-kD protein in CD3 complexes expressed on
stimulated but not on unstimulated ex vivo    T cells. This
protein was also observed in surface CD3 complexes when
anti–TCR-  and anti-CD3  mAbs (Fig. 1 and unpublished
data) were used to immunoprecipitate TCR complexes
from stimulated    T cells. Examination of the kinetics of
appearance of the 26-kD protein in the     TCR after
TCR activation and expansion showed that it first appeared
in surface    TCRs at 5 d after activation and was still ob-
served at the latest time point of the experiment (12 d after
activation; unpublished data). The 26-kD protein was also
detected in the CD3 complexes expressed by polyclonal   
T cell populations from TCR-  /  mice after TCR acti-
vation and expansion (unpublished data). Comparison of
*Abbreviations used in this paper: 2-D, two-dimensional; FcR , Fc R1  
chain; iIEL, intestinal intraepithelial lymphocyte; PNGase, peptide-N-
glycosidase.1357 Hayes et al.
the CD3 complexes on stimulated    and    T cells by
2-D SDS-PAGE analysis demonstrated that the 26-kD pro-
tein, detected in TCR complexes on activated    T cells,
migrated similarly to CD3  (Fig. 1). Therefore, these re-
sults demonstrated that activation and expansion induce the
inclusion of a protein, comparable in mass and mobility to
CD3 , in the    TCR.
CD3  Is Not a Component of the TCR Expressed by In
Vitro Activated and Expanded    T Cells. To determine
whether the 26-kD protein in the    TCR was in fact
CD3 , fully assembled TCR complexes from stimulated
   T cells were recovered by immunoprecipitation with
anti–TCR-  mAb and then immunoblotted with anti-
CD3  serum. As shown previously (6) and in Fig. 2 A, lit-
tle or no CD3  was detected in anti–TCR-  immunopre-
cipitates from ex vivo    T cells. In contrast, CD3  was
detected in anti–TCR-  immunoprecipitates from ex vivo
   T cells (Fig. 2 A). Interestingly, the anti-CD3  serum
did not react with any protein in the    TCRs recovered
from stimulated    T cells (Fig. 2 A). This finding is even
more striking given the fact that total cellular CD3  pro-
tein was increased in stimulated    T cell extracts relative
to ex vivo    T cell extracts (Fig. 2 B). These data agree
with those of our previous study, in which we reported
that the TCR-  and TCR-  chains are unable to pair effi-
ciently with CD3   dimers (6).
As the TCR-  chain in the transgenic    TCR utilizes
the C 1 gene segment, we next determined whether
TCR-  chains using the C 4 gene segment (the other
major C  gene segment expressed in peripheral    T cells;
reference 13) could pair with CD3   dimers. Using the
anti-V 1 mAb (13), we selectively activated V 1-J 4-C 4–
bearing    T cells from TCR-  /  mice. 2-D SDS-PAGE
analysis of surface biotinylated TCR subunits from stimu-
Figure 1. Effect of in vitro activation and expansion on the subunit
composition of   - and    TCR complexes. Ex vivo    and    T cells
were purified from the lymph nodes of B6 and    TCR Tg mice, respec-
tively. Stimulated    and    T cells, from B6 and    TCR Tg mice, re-
spectively, were generated as described in Materials and Methods. Surface
proteins were labeled with biotin and    and    TCR complexes were
immunoprecipitated using anti-TCR mAbs (H57–597 and UC7–13D5,
respectively) or anti-TCR-  mAb (H146). Immunoprecipitated proteins
were resolved by nonreducing/reducing 2-D SDS-PAGE. ABC-HRP
and chemiluminescence were used to visualize surface biotinylated pro-
teins. The positions of the CD3 subunits and the unknown 26-kD sub-
unit (?) are marked.
Figure 2. Biochemical analysis of CD3 complexes expressed by stimu-
lated    T cells. (A) Lysates from 20   106 ex vivo    and    T cells and
stimulated    T cells were immunoprecipitated with anti–TCR-  mAb
(H146). Immunoprecipitated proteins were resolved by SDS-PAGE and
immunoblotted with anti-CD3  serum. The blot was subsequently
stripped and probed with anti-CD3  to assess the efficiency of immuno-
precipitation. (B) Total cellular CD3  protein levels in ex vivo and in
stimulated    and    T cells. Extracts were made from 10   106 cells and
0.3   106 cell equivalents were then analyzed by immunoblotting with
anti-CD3  serum. (C) Lysates from 25   106 stimulated V 1-J 4-C 4 
   T cells and B6 thymocytes were immunoprecipitated with anti-TCR
mAbs (UC7–13D5 and H57–597, respectively). Immunoprecipitated
proteins were resolved by SDS-PAGE and immunoblotted with anti-
CD3  serum. The blot was subsequently stripped and probed with anti-
CD3  to assess the efficiency of immunoprecipitation. (D) 20   106
stimulated    T cells from nontransgenic CD3  /  mice were surface
biotinylated, lysed, and incubated with anti-CD3  mAb (145–2C11). Im-
munoprecipitated proteins were resolved by nonreducing/reducing 2-D
SDS-PAGE. Biotinylated TCR subunits were detected with ABC-HRP
and chemiluminescence. The positions of the CD3 subunits and the un-
known 26-kD subunit (?) are marked.1358 Modification of the CD3  Subunit of the    TCR after Activation
lated C 4-bearing    T cells also demonstrated the inclu-
sion of a 26-kD protein in the    TCR after activation and
expansion (unpublished data). However, this protein was
not CD3  as assessed by Western blot analysis of anti-  
TCR immunoprecipitates (Fig. 2 C). Taken together,
these results suggested that most    T cells, whether stimu-
lated or unstimulated, do not contain CD3  as a compo-
nent of their TCRs.
To verify that the 26-kD protein detected in the   
TCR after activation and expansion was not CD3 , we
analyzed the subunit composition of TCRs expressed by
stimulated    T cells from CD3  /  mice (11). Signifi-
cantly, the surface CD3 complexes on stimulated CD3  / 
   T cells were similar in composition to those on stimu-
lated CD3  /     T cells (Figs. 1 and 2 D, and unpub-
lished data), thereby confirming that the 26-kD protein
detected in the    TCR after TCR activation and expan-
sion was not CD3 . Based on these results, we conclude
that activation and expansion induce changes in the CD3
complex of the    TCR but do not induce the inclusion
of CD3 .
CD3  Is Modified After TCR Stimulation in Both    and
   T Cells. The 26-kD protein identified in the    TCR
after activation and expansion could potentially be a
modified form of one of the other invariant TCR sub-
units, with the modification being differential N-glycosy-
lation, ubiquitination, and/or phosphorylation. To deter-
mine whether this protein is a differentially glycosylated
form of an invariant TCR subunit, we treated immuno-
precipitated TCR proteins with PNGase F, a glycosidase
that removes N-linked glycans at the asparagine residue.
As shown in Fig. 3 A, three surface biotinylated proteins
were detected in the CD3 complex in untreated anti-
CD3  immunoprecipitates from stimulated    T cells, as
predicted by the 2-D SDS-PAGE analysis (Fig. 1). How-
ever, only two proteins, identical in mass to CD3  and
CD3 , were detected in the CD3 complex after PNGase
F treatment. This finding suggested that the 26-kD protein
may be a differentially glycosylated form of CD3 , be-
cause CD3  is the only invariant subunit other than CD3 
to have an N-linked glycosylation site (16). To test this,
we repeated the experiment using anti–TCR-  mAb to
immunoprecipitate mature    TCR complexes and anti-
CD3  serum to immunoblot for CD3  in the    TCR
complex. In anti–TCR-  immunoprecipitates that were
not treated with the glycosidase, we detected at least four
forms of CD3 , ranging in mass from 21–26-kD, in stim-
ulated    T cells (Fig. 3 B).
Figure 3. Modification of the
CD3  subunit after in vitro acti-
vation and expansion. (A) 30  
106 ex vivo    (     TCR Tg
[Tg] CD3  /  mice) and stimu-
lated     T cells (Tg CD3  / 
and Tg CD3  /  mice) were
surface biotinylated, lysed, and
incubated with anti-CD3  mAb
(145–2C11). Immunoprecipi-
tated proteins were either treated
with PNGase F or left untreated
and resolved by reducing SDS-
PAGE. ABC-HRP and chemi-
luminescence were used to vi-
sualize surface biotinylated
proteins. The positions of the
CD3 subunits and the unknown
26-kD subunit (?) are marked.
(B) Lysates from 30   106 ex
vivo    (Tg CD3  /  mice) and
stimulated     T cells (Tg
CD3  /  and Tg CD3  / 
mice) were immunoprecipitated
with anti-TCR-  mAb (H146)
and then treated with PNGase F
or left untreated. Digested and
undigested TCR proteins were
resolved by reducing SDS-
PAGE and immunoblotted with
anti-CD3  serum. (C) Lysates
from 30   106 ex vivo    (B6
mice) and stimulated    T cells
(B6 and CD3  /  mice) were
immunoprecipitated with anti-
CD3  (145–2C11) or anti-TCR-  mAb (H146). Immunoprecipitated proteins were resolved by reducing SDS-PAGE and immunoblotted with
anti-CD3  serum. (D) Stimulated    and    T cells from CD3  /  mice were generated as described in Materials and Methods. Surface proteins on
equivalent numbers of cells were labeled with biotin and TCR complexes were immunoprecipitated using the anti-CD3  mAb (145–2C11). Immuno-
precipitated proteins were resolved by nonreducing/reducing 2-D SDS-PAGE. ABC-HRP and chemiluminescence were used to visualize surface bio-
tinylated proteins. The exposure time for each blot is identical. The positions of the CD3  and the modified forms of CD3  are marked.1359 Hayes et al.
After PNGase F treatment, all forms of CD3  were re-
duced to 16 kD, the core protein size of CD3 . Interest-
ingly, when we immunoprecipitated biotinylated TCR
proteins with the anti-CD3  mAb (H25), we did not de-
tect the modified forms of CD3  while we did detect the
21-kD form of CD3  (unpublished data), suggesting that
the differential glycosylation of CD3  affects the binding of
the H25 mAb. Therefore, these results suggested that the
26-kD protein in the CD3 complex of the    TCR is a
differentially glycosylated form of CD3 . As PNGase F
treatment of this 26-kD protein removed only N-linked
sugars and reduced its mass to 16 kD, these results indicate
that CD3  is modified only by differential glycosylation
and not additionally by ubiquitination or phosphorylation,
which are covalent modifications that are not affected by
glycosidase treatment.
Because activation and expansion induced changes in the
glycosylation pattern of the CD3  subunit in    T cells, it
was of particular interest to determine whether this modifi-
cation also occurred in stimulated    T cells. To test this,
we repeated the preceding experiment using    T cells
that were activated and expanded in conditions similar to
those used for    T cells. Western blot analysis was per-
formed on anti-CD3  immunoprecipitates from stimulated
   T cells from CD3  /  mice. Interestingly, while differ-
entially glycosylated forms of CD3  were detected in stim-
ulated    T cells, we did not observe the 26-kD form (Fig.
3 C). Next, we determined whether any of the modified
forms of CD3  were incorporated into fully assembled   
TCRs by immunoblotting anti–TCR-  immunoprecipi-
tates with anti-CD3  serum. As shown in Fig. 3 C, only
very low amounts of the modified forms of CD3  were
detected in fully assembled TCRs expressed by    T cells. 
Because the TCRs on stimulated    T cells lack CD3 
and contain the differentially glycosylated forms of CD3 ,
it is conceivable that the presence of CD3  hinders the in-
corporation of modified CD3  into the    TCR complex.
To test this, we examined    TCRs from stimulated    T
cells from CD3  /  mice for the presence of CD3  modi-
fication. While we detected modified forms of CD3  in
CD3  /     T cells, we did not detect any CD3  (includ-
ing the 21-kD form) associated with TCR-  (Fig. 3 C).
The inability to detect CD3  in the anti–TCR-  immuno-
precipitate may be due to the instability and/or extremely
low surface expression of CD3 -deficient    TCR com-
plexes (reference 11 and unpublished data). Therefore, we
analyzed the subunit composition of    TCRs expressed
on stimulated CD3  /     T cells by surface biotinylation
and 2-D SDS-PAGE. The amount of modified CD3  de-
tected in surface CD3 -deficient    TCRs was negligible,
similar to the amount detected in intact    TCRs (Figs. 1
and 3, C and D). These findings suggest that modified
forms of CD3  are major components of TCRs on stimu-
lated    T cells but not on stimulated    T cells. The rea-
son why these modified forms of CD3  are incorporated at
a high frequency into the fully assembled    TCR but not
into the fully assembled    TCR is unknown, but it may
be due to the ability of the TCR- /TCR-  chains to bind
more efficiently than the TCR- /TCR-  chains to differ-
entially glycosylated CD3   dimers. This ability of the   
TCR to accommodate CD3   dimers with bulkier sugar
groups demonstrates yet another fundamental difference in
   and    TCR structure.
Modified CD3  Is Detected in iIELs. While our results
established that in vitro activation and expansion are able
to induce modification of the CD3  chain in both    and
   T cells, it remained unclear whether this modification
occurs in vivo. To address this, we analyzed the subunit
composition of the TCRs expressed by iIELs, which are
50%    TCR  and display an activated phenotype (un-
published data and reference 17). As predicted from our
analysis of TCR complexes on ex vivo and activated    T
cells, little or no CD3  was detected in TCR complexes
on    TCR  iIELs (Fig. 4 A). When we assayed for mod-
ified forms of CD3 , higher molecular weight forms of
CD3  were detected in anti-   TCR immunoprecipitates
of iIEL lysates, albeit at a much lower level than that ob-
served for in vitro activated and expanded    T cells (Figs.
4 A and 3 B).
 The lower level of CD3  modification may be due to
the fact that    TCR  iIELs are not homogeneous in their
state of activation and, consequently, there may be fewer
cells that express the differentially glycosylated forms of
CD3 . To examine the extent of CD3  modification in
iIELs, we recovered CD3 dimers by immunoprecipitating
unfractionated iIEL lysates with anti-CD3  mAb and as-
sayed for the presence of modified CD3  to determine
whether a change in the glycosylation pattern of CD3  oc-
curred in iIELs. As shown in Fig. 4 B, differentially glyco-
sylated forms of CD3 , but not the 26-kD form, were de-
tected in iIELs (Fig. 4 B). These results demonstrated that
Figure 4. Detection of differentially glycosylated forms of CD3  in
iIELs. (A) Lysate from 30   106 iIELs from B6 mice was subjected to se-
rial immunoprecipitations with anti-  TCR and then anti-  TCR
mAbs (UC7–13D5 and H57–597, respectively). Immunoprecipitated
proteins were resolved by reducing SDS-PAGE and immunoblotted with
anti-CD3  serum. The blot was subsequently stripped and immunoblotted
with anti-CD3  serum. (B) Lysates from 20   106 ex vivo iIELs from B6
mice were immunoprecipitated with anti-CD3  (145–2C11). Immuno-
precipitated proteins were resolved by reducing SDS-PAGE and immu-
noblotted with anti-CD3  serum.1360 Modification of the CD3  Subunit of the    TCR after Activation
CD3  modification is detected and therefore, can occur in
activated mature T cells in vivo.
Many surface glycoproteins have been reported to un-
dergo changes in glycosylation patterns during develop-
ment and after activation (for reviews, see references 18
and 19). For example, two recent studies have shown that
the O-linked sugars on CD8 play a role in cognate/non-
cognate binding of MHC class I tetramers to thymocytes
(20, 21). The CD8 expressed on immature CD4 CD8 
thymocytes is capable of binding MHC class I tetramers
from various MHC alleles and haplotypes. This is not the
case for mature CD8  thymocytes and peripheral CD8  T
cells, as their CD8 is sialylated and can only bind to the ap-
propriate peptide–MHC class I complex (20, 21). Although
the importance of this change in CD8 glycosylation is un-
known, both groups speculated that the differential binding
of CD8 molecules to MHC class I molecules during devel-
opment may play a role in selection by affecting the span of
time a developing thymocyte spends interacting with class
I–bearing thymic stroma (20, 21).
Similarly, it is not known how the glycosylation status of
CD3  affects    TCR signaling and    T cell function.
However, using mice with a targeted mutation in a carbo-
hydrate-modifying enzyme as a guide (22), we can specu-
late as to the role of this modification in    T cell biology.
It is known that a typical N-glycan is 30 Å in length, com-
parable to an Ig domain (23). Because in vitro activation
and expansion increase the mass of the carbohydrate group
on CD3 , it is conceivable that the carbohydrate chain on
CD3  is elongated through addition of branched sugars
(18). An increase in carbohydrate chain length on CD3  
dimers could cause the      TCR complexes in the cell
membrane of stimulated    T cells to be spaced further
apart, making it more difficult to cross-link surface   
TCR complexes and thereby, increasing the threshold of
signaling for the    TCR (22, 23). In practice, this may be
a mechanism by which    T cells that recognize self-heat
shock proteins or stress antigens establish a baseline thresh-
old for signaling after their first encounter with self-anti-
gens and then are able to distinguish between normal and
stressed cells in subsequent encounters.
Modification in CD3  glycosylation may not result in
carbohydrate chain elongation but may result in the linkage
of different sugar residues to the CD3  chain. Such
changes in carbohydrate moieties may affect the binding of
endogenous lectins, such as the galectin family of carbohy-
drate-binding proteins, to the TCR complex (22). Because
galectins have been shown to regulate T cell signaling and
apoptosis (for a review, see reference 24), it is conceivable
that the inclusion of modified CD3  in the    TCR may
facilitate the binding of galectins and increase the suscepti-
bility of stimulated    T cells to apoptosis. If this is true,
this may explain why, unlike    T cells, no memory re-
sponse has been described for murine    T cells (for a re-
view, see reference 25). While future studies are required
to determine the importance of this modification, the fact
that another alteration in    TCR subunit composition,
inclusion of FcR , occurs after activation and expansion
(6) suggests that the signaling potential of the    TCR may
be profoundly affected.
In summary, we have described an activation and expan-
sion induced modification in the CD3  subunit of the
TCR that consists of differential glycosylation at its single
site of N-linked glycosylation. While this modification
could occur in all T cells, the modified forms of CD3 
were only incorporated at a high frequency into the   
TCR. One of the differentially glycosylated forms of
CD3  that was included in the    TCR had a mass and
mobility in 2-D SDS-PAGE similar to CD3 . We believe
that it is this modified form of CD3  that was initially
identified as CD3  in early studies of    TCR structure,
because CD3  is not detected in    TCR complexes on
primary and in vitro activated and expanded    T cells.
We thank Drs. Karl Pfeifer, Elizabeth Shores, and Connie Sommers
for helpful advice and critical review of the manuscript.
Submitted: 12 July 2002
Revised: 9 September 2002
Accepted: 10 October 2002
References
1. Punt, J.A., J.L. Roberts, K.P. Kearse, and A. Singer. 1994.
Stoichiometry of the T cell antigen receptor (TCR) com-
plex: each TCR/CD3 complex contains one TCR , one
TCR , and two CD3  chains. J. Exp. Med. 180:587–593.
2. Qian, D., A.I. Sperling, D.W. Lanki, Y Tatsumi, T.A. Bar-
rett, J.A. Bluestone, and F.W. Fitch. 1993. The   chain of
the high-affinity receptor for IgE is a major functional sub-
unit of the T-cell antigen receptor complex in    T lympho-
cytes. Proc. Natl. Acad. Sci. USA. 90:11875–11879.
3. Guy-Grand, D., B. Rocha, P. Mintz, M. Malassis-Seris, F.
Selz, B Malissen, and P. Vassalli. 1994. Different use of T cell
receptor transducing modules in two populations of gut in-
traepithelial lymphocytes are related to distinct pathways of T
cell differentiation. J. Exp. Med. 180:673–679.
4. Heiken, H., R.-J. Schulz, J.V. Ravetch, E.L. Reinherz, and
S. Koyasu. 1996. T lymphocyte development in the absence
of Fc  receptor I  subunit: analysis of thymic-dependent and
independent    and    pathways. Eur. J. Immunol. 26:1935–
1943.
5. Shores, E.W., M. Ono, T. Kawabe, C.L. Sommers, T. Tran,
L. Lui, M.C. Udey, J. Ravetch, and P.E. Love. 1998. T cell
development in mice lacking all T cell receptor family mem-
bers ( ,  , and Fc RI ). J. Exp. Med. 187:1093–1101.
6. Hayes, S.M., and P.E. Love. 2002. Distinct structure and sig-
naling potential of the   TCR complex. Immunity. 16:827–
838.
7. Park, S.W., H. Arase, K. Wakizaka, N. Hirayama, S. Masaki,
S. Sato, J.V. Ravetch, and T. Saito. 1995. Differential contri-
bution of the FcR  chain to the surface expression of the T
cell receptor among T cells localized in epithelia: analysis of
FcR -deficient mice. Eur. J. Immunol. 25:2107–2110.
8. Cron, R.Q., F. Koning, W.L. Maloy, D. Pardoll, J.E. Coli-
gan, and J.A. Bluestone. 1988. Peripheral murine CD3 ,
CD4 , CD8  T lymphocytes express novel T cell receptor
   structures. J. Immunol. 141:1074–1082.
9. Mombaerts, P., E. Mizoguchi, M.J. Grusby, L.H. Glimcher,
A.K. Bhan, and S. Tonegawa. 1993. Spontaneous develop-1361 Hayes et al.
ment of inflammatory bowel disease in T cell receptor mu-
tant mice. Cell. 75:274–282.
10. Sim, G.-K., C. Olsson, and A. Augustin. 1995. Commitment
and maintenance of the    and    T cell lineages. J. Immu-
nol. 154:5821–5831.
11. Dave, V.P., Z. Cao, C. Browne, B. Alarcon, G, Fernandez-
Miguel, J. Lafaille, A. de la Hera, S. Tonegawa, and D.J.
Kappes. 1997. CD3  deficiency arrests development of the
   but not    T cell lineage. EMBO J. 16:1360–1370.
12. Laky, K., L. Lefrançois, E.G. Lingenheld, H. Ishikawa, J.M.
Lewis, S. Olson, K. Suzuki, R.E. Tigelaar, and L. Pudding-
ton. 2000. Enterocyte expression of interleukin 7 induces de-
velopment of    T cells and Peyer’s Patches. J. Exp. Med.
191:1569–1580.
13. Pereira, P., D. Gerber, S.Y. Huang, and S. Tonegawa. 1995.
Ontogenic development and tissue distribution of V 1-
expressing  / -T lymphocytes in normal mice. J. Exp. Med.
182:1921–1930.
14. Berger, M.A., M. Carleton, M. Rhodes, J.M. Sauder, S.
Trop, R.L. Dunbrack, P. Hugo, and D.L. Wiest. 2000. Iden-
tification of a novel preTCR isoform in which the accessibil-
ity of the TCR-  subunit is determined by occupancy of the
missing V domain of pre-T . Int. Immunol. 12:1579–1591.
15. Sommers, C.L., R.L. Rabin, A. Grinberg, H.C. Tsay, J. Far-
ber, and P.E. Love. 1999. A role for the Tec family tyrosine
kinase Txk in T cell activation and thymocyte selection. J.
Exp. Med. 190:1427–1438.
16. Klausner, R.D., J. Lippincott-Schwartz, and J.S. Bonifacino.
1990. The T cell antigen receptor: insights into organelle bi-
ology. Annu. Rev. Immunol. 6:403–431.
17. Sydora, B.C., P.F. Mixter, H.R. Holcombe, P. Eghtesady,
K. Williams, M.C. Amaral, A. Nel, and M. Kronenberg.
1993. Intestinal intraepithelial lymphocytes are activated and
cytolytic but do not proliferate as well as other T cells in re-
sponse to mitogenic signals. J. Immunol. 150:2179–2191.
18. Lowe, J.B. 2001. Glycosylation, immunity, and autoimmu-
nity. Cell. 104:809–812.
19. Baum, L.G. 2002. Developing a taste for sweets. Immunity.
16:5–8.
20. Moody, A.M., D. Chui, P.A. Reche, J.J. Priatel, J.D. Math,
and E.L. Reinherz. 2001. Developmentally regulated glyco-
sylation of the CD8   coreceptor stalk modulates ligand
binding. Cell. 107:501–512.
21. Daniels, M.A., L. Devine, J.D. Miler, J.M. Moser, A.E.
Lukacher, J.D. Altman, P. Kavathas, K.A. Hogquist, and S.C.
Jameson. 2001. CD8 binding to MHC class I molecules is in-
fluenced by T cell maturation and glycosylation. Immunity.
15:1051–1061.
22. Demetriou, M., M. Granovsky, S. Quaggin, and J.W. Den-
nis. 2001. Negative regulation of T cell activation and au-
toimmunity by Mgat5 N-glycosylation. Nature. 409:733–
739.
23. Rudd, P.M., M.R. Wormald, R.L. Stanfield, M. Huang, N.
Mattsson, J.A. Speir, J.A. DiGennaro, J.S. Fetrow, R.A.
Dwek, and I.A. Wilson. 1999. Roles for glycosylation of cell
surface receptors involved in cellular immune recognition. J.
Mol. Biol. 293:351–366.
24. Rabinovich, G.A., L.G. Baum, N. Tinari, R. Paganelli, C.
Natoli, F.-T. Liu, and S. Iacobelli. 2002. Galectins and their
ligands: amplifiers, silencers or tuners of the inflammatory re-
sponse? Trends Immunol. 23:313–320.
25. Hayday, A.C. 2000.    cells: a right time and a right place for
a conserved third way of protection. Annu. Rev. Immunol. 18:
975–1026.